Vaccibody As Stock Current Asset
| VACCDelisted Stock | USD 2.23 0.04 1.83% |
Vaccibody As fundamentals help investors to digest information that contributes to Vaccibody's financial success or failures. It also enables traders to predict the movement of Vaccibody Stock. The fundamental analysis module provides a way to measure Vaccibody's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vaccibody stock.
Vaccibody |
Vaccibody As Company Current Asset Analysis
Vaccibody's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
CompetitionIn accordance with the recently published financial statements, Vaccibody As has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all Norway stocks is 100.0% higher than that of the company.
Vaccibody Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vaccibody's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vaccibody could also be used in its relative valuation, which is a method of valuing Vaccibody by comparing valuation metrics of similar companies.Vaccibody is currently under evaluation in current asset category among its peers.
Vaccibody Fundamentals
| Return On Equity | -0.23 | |||
| Return On Asset | -0.15 | |||
| Operating Margin | (77.18) % | |||
| Current Valuation | 32.03 M | |||
| Shares Outstanding | 38.55 M | |||
| Shares Owned By Insiders | 3.45 % | |||
| Shares Owned By Institutions | 49.84 % | |||
| Number Of Shares Shorted | 159.22 K | |||
| Price To Earning | 12.63 X | |||
| Price To Book | 0.36 X | |||
| Price To Sales | 2.31 X | |||
| Revenue | 44.7 M | |||
| Gross Profit | 44.7 M | |||
| EBITDA | 869 K | |||
| Net Income | 5.32 M | |||
| Cash And Equivalents | 192.33 M | |||
| Cash Per Share | 5.17 X | |||
| Total Debt | 8.77 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 18.60 X | |||
| Book Value Per Share | 5.64 X | |||
| Cash Flow From Operations | (14.43 M) | |||
| Short Ratio | 0.08 X | |||
| Earnings Per Share | (1.59) X | |||
| Target Price | 9.31 | |||
| Number Of Employees | 33 | |||
| Beta | -0.39 | |||
| Market Capitalization | 192.73 M | |||
| Total Asset | 270.2 M | |||
| Retained Earnings | (103.24 M) | |||
| Working Capital | 200.8 M | |||
| Z Score | 13.71 | |||
| Net Asset | 270.2 M |
About Vaccibody Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vaccibody As's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vaccibody using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vaccibody As based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| S | SentinelOne | |
| CRM | Salesforce | |
| MSFT | Microsoft |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Vaccibody Stock
If you are still planning to invest in Vaccibody As check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vaccibody's history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |